BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating

Taysha Gene Therapies (TSHA) has received strong analyst endorsement, with BofA Securities initiating Buy coverage and an $8.00 price target, while Cantor Fitzgerald maintained its Overweight rating ($13 target) and Canaccord Genuity raised its target to $11. This positive sentiment is driven by the promising clinical and regulatory progress of TSHA-102, its gene therapy for Rett syndrome, which has shown early efficacy in enabling patients to gain developmental milestones and secured FDA alignment on a pivotal trial design expected to commence in Q3 2025. The company recently completed a $200 million offering and increased authorized shares to fund its pipeline, positioning TSHA-102 as a potential first-in-class disease-modifying treatment, though its market valuation has yet to fully reflect this optimism.

Analysis

Taysha Gene Therapies (TSHA) is experiencing a wave of positive analyst sentiment centered on the clinical and commercial potential of its lead asset, TSHA-102, a gene therapy for Rett syndrome. BofA Securities has initiated coverage with a Buy rating and an $8.00 price target, representing a significant premium to its current $2.55 trading price. This new coverage is complemented by Cantor Fitzgerald maintaining its Overweight rating with a $13 target and Canaccord Genuity raising its target to $11 from $9. The core driver of this optimism is the therapy's potential to be the first disease-modifying treatment for Rett syndrome, supported by early clinical data where patients demonstrated the ability to gain or regain developmental milestones. A key de-risking event has been the company's alignment with the FDA on a pivotal trial design, with initiation planned for Q3 2025. Financially, Taysha has strengthened its position through a recent $200 million offering and holds more cash than debt. Strategically, the company secured stockholder approval to increase authorized shares from 400 million to 700 million, preparing for future capital needs to advance its pipeline. Despite a 45% stock price increase over the last six months, the article suggests the market has not yet fully priced in this optimistic outlook.

Key Decisions for Investors

• Given the strong analyst consensus with price targets implying significant upside, investors with a high risk tolerance for clinical-stage biotechnology could consider a speculative long position in TSHA.
• Investors should closely monitor near-term catalysts, including the upcoming disclosure of the NGNE registrational trial details and the initiation of the TSHA-102 pivotal trial in Q3 2025, as progress is critical to validating the current thesis.
• While the balance sheet is currently solid post-offering, the recent approval to increase authorized shares signals potential future dilution, which should be factored into position sizing and long-term valuation models.